In the recurrent ovarian cancer setting, pazopanib, a multitargeted TKI affecting VEGFR, PDGFR and c-Kit, was evaluated in a randomized phase 2 trial in 74 patients with a platinum-resistant disease in combination with paclitaxel, demonstrating a 3-month improvement in PFS (HR 0.42; p = 0.002) [84]. The gene discussed is KDR; the disease is ovarian carcinoma.